Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Participants' written informed consent in low-risk pragmatic clinical trials with medicines.

Dal-Ré R.

Expert Rev Clin Pharmacol. 2020 Mar 9:1-6. doi: 10.1080/17512433.2020.1732816. [Epub ahead of print]

PMID:
32073940
2.

Unperceived similarities between clinical trials and quantum physics.

Dal-Ré R.

Br J Clin Pharmacol. 2020 Feb;86(2):192-193. doi: 10.1111/bcp.14126. Epub 2020 Jan 14. No abstract available.

PMID:
31943305
3.

On the semantics of clinical trials. The case of a 'pragmatic' trial in Alzheimer's disease.

Dal-Ré R.

Eur J Neurol. 2020 Mar;27(3):e14. doi: 10.1111/ene.14141. Epub 2019 Dec 23. No abstract available.

PMID:
31823426
4.

Reporting the details of consent procedures in clinical trials.

Dal Ré R, Solberg B, Fuhr U, Eriksson S.

J Clin Epidemiol. 2020 Jan;117:150-151. doi: 10.1016/j.jclinepi.2019.09.014. Epub 2019 Sep 19. No abstract available.

PMID:
31542507
5.
6.

Reasons for and time to retraction of genetics articles published between 1970 and 2018.

Dal-Ré R, Ayuso C.

J Med Genet. 2019 Nov;56(11):734-740. doi: 10.1136/jmedgenet-2019-106137. Epub 2019 Jul 12. Erratum in: J Med Genet. 2020 Mar 31;:.

7.

Analysis of biomedical Spanish articles retracted between 1970 and 2018.

Dal-Ré R.

Med Clin (Barc). 2020 Feb 28;154(4):125-130. doi: 10.1016/j.medcli.2019.04.018. Epub 2019 Jun 22. English, Spanish.

PMID:
31239080
8.

Analysis of retracted articles on medicines administered to humans.

Dal-Ré R.

Br J Clin Pharmacol. 2019 Sep;85(9):2179-2181. doi: 10.1111/bcp.14021. Epub 2019 Jun 24. No abstract available.

PMID:
31236989
9.

A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines.

Dal-Ré R, Avendaño-Solà C, de Boer A, James SK, Rosendaal FR, Stephens R, Ioannidis JPA.

J Clin Epidemiol. 2019 Oct;114:60-71. doi: 10.1016/j.jclinepi.2019.06.007. Epub 2019 Jun 15.

PMID:
31212001
10.

Low risk pragmatic trials do not always require participants' informed consent.

Dal-Ré R, Avendaño-Solà C, Bloechl-Daum B, de Boer A, Eriksson S, Fuhr U, Holm S, James SK, Mentz RJ, Perucca E, Rosendaal FR, Treweek S.

BMJ. 2019 Mar 27;364:l1092. doi: 10.1136/bmj.l1092. No abstract available. Erratum in: BMJ. 2019 Apr 1;365:l1518.

PMID:
30917969
11.

The misleading use of the term pragmatic in pre-licensing medicine trials.

Dal-Ré R.

Eur J Clin Pharmacol. 2019 Aug;75(8):1033-1035. doi: 10.1007/s00228-019-02672-7. Epub 2019 Mar 26. No abstract available.

PMID:
30915519
12.
13.

Plan S: Funders are committed to open access to scientific publication.

Dal-Ré R.

Eur J Clin Invest. 2019 Mar 6:e13100. doi: 10.1111/eci.13100. [Epub ahead of print] No abstract available.

PMID:
30838638
14.

[Publications in potential predatory journals].

Dal-Ré R.

An Pediatr (Barc). 2019 Jun;90(6):409-410. doi: 10.1016/j.anpedi.2019.01.010. Epub 2019 Feb 16. Spanish. No abstract available.

15.

[Transparency of Spanish medical journals towards their readers and authors].

Dal-Ré R.

An Pediatr (Barc). 2019 Jul;91(1):67-70. doi: 10.1016/j.anpedi.2018.12.002. Epub 2019 Jan 11. Spanish. No abstract available.

16.

Who are the Spanish sponsors of the higher number of non-commercial clinical trials with medicines and of the reporting of their results?

Dal-Ré R.

Med Clin (Barc). 2019 Jul 5;153(1):e3-e4. doi: 10.1016/j.medcli.2018.10.017. Epub 2018 Dec 4. English, Spanish. No abstract available.

PMID:
30527216
17.
18.

Are journals following the ICMJE recommendations complying with conflicts of interest disclosure policies.

Dal-Ré R, Marušić A.

Eur J Intern Med. 2018 Nov;57:e17-e19. doi: 10.1016/j.ejim.2018.07.025. Epub 2018 Jul 31. No abstract available.

PMID:
30076090
19.

Assessment of Pragmatism in Recently Published Randomized Clinical Trials.

Janiaud P, Dal-Ré R, Ioannidis JPA.

JAMA Intern Med. 2018 Sep 1;178(9):1278-1280. doi: 10.1001/jamainternmed.2018.3321. Review. No abstract available.

20.

Getting more light into the dark room of editorial conflicts of interest.

Marušić A, Dal-Ré R.

J Glob Health. 2018 Jun;8(1):010101. doi: 10.7189/jogh.08.010101. No abstract available.

21.

Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines.

Dal-Ré R, Abad-Santos F, Avendaño-Solà C.

Med Clin (Barc). 2019 Jan 18;152(2):78-79. doi: 10.1016/j.medcli.2018.04.013. Epub 2018 May 18. English, Spanish. No abstract available.

PMID:
29784477
22.

Misleading information generated in medical journals that reaches the citizen electronically.

Dal-Ré R.

Med Clin (Barc). 2018 Nov 9;151(9):359-361. doi: 10.1016/j.medcli.2018.03.026. Epub 2018 May 3. English, Spanish. No abstract available.

PMID:
29731132
23.

Efficacy and effectiveness: The wrong use of different terms.

Dal-Ré R, Rosendaal F.

Eur J Intern Med. 2018 Aug;54:e17-e18. doi: 10.1016/j.ejim.2018.04.022. Epub 2018 May 3. No abstract available.

PMID:
29730083
24.

Financial conflicts of interest in medical journals.

Dal-Ré R.

Emergencias. 2018 Jun;30(3):201-204. English, Spanish. No abstract available.

25.

How to improve the integrity of clinical trial articles.

Dal-Ré R.

Rev Psiquiatr Salud Ment. 2018 Oct - Dec;11(4):189-191. doi: 10.1016/j.rpsm.2018.02.002. Epub 2018 Apr 4. English, Spanish. No abstract available.

PMID:
29625891
26.

What most influent psychiatry journals do not show.

Dal-Ré R.

Rev Psiquiatr Salud Ment. 2018 Oct - Dec;11(4):256-257. doi: 10.1016/j.rpsm.2018.02.001. Epub 2018 Apr 4. English, Spanish. No abstract available.

PMID:
29625890
27.

Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?

Dal-Ré R, Janiaud P, Ioannidis JPA.

BMC Med. 2018 Apr 3;16(1):49. doi: 10.1186/s12916-018-1038-2.

28.

[High impact pediatric journals in the back stage].

Dal-Ré R.

An Pediatr (Barc). 2018 May;88(5):295-296. doi: 10.1016/j.anpedi.2018.02.001. Epub 2018 Mar 24. Spanish. No abstract available.

29.

Preregistration and publication of nonregulated intervention trials are here to stay (letter commenting Wallach et al 2018, 93, 88-93).

Dal-Ré R.

J Clin Epidemiol. 2018 Jul;99:167-168. doi: 10.1016/j.jclinepi.2018.02.014. Epub 2018 Feb 23. No abstract available.

PMID:
29481856
30.

[Easing access to all information should be mandatory to medical journals].

Dal-Re R, Ayuso C.

Rev Neurol. 2018 Feb 16;66(4):135. Spanish.

31.

Clinical Trials Transparency: Where Are We Today?

Dal-Ré R.

Trends Cancer. 2018 Jan;4(1):1-3. doi: 10.1016/j.trecan.2017.11.003. Epub 2017 Nov 22. Review.

PMID:
29413417
32.

Is it time to discuss on low-intervention clinical trials without participants' informed consent?

Dal-Ré R, Carné X.

Med Clin (Barc). 2018 May 11;150(9):345-347. doi: 10.1016/j.medcli.2017.10.027. Epub 2017 Nov 28. English, Spanish. No abstract available.

PMID:
29196035
33.

Journals' TOP guidelines transparency level should be disclosed.

Dal-Ré R.

Eur J Clin Pharmacol. 2018 Feb;74(2):249-250. doi: 10.1007/s00228-017-2370-8. Epub 2017 Nov 9. No abstract available.

PMID:
29124303
34.

[Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].

Dal-Ré R, Lopez de Munain A, Ayuso C.

Rev Neurol. 2017 Oct 16;65(8):373-380. Review. Spanish.

35.

Access to Anonymized Individual Participant Clinical Trials Data: A Radical Change of Mind by the Most Prestigious Medical Journals.

Dal-Ré R.

Arch Bronconeumol. 2018 Feb;54(2):65-67. doi: 10.1016/j.arbres.2017.07.025. Epub 2017 Sep 18. English, Spanish. No abstract available.

PMID:
28927858
36.

Patients' beliefs regarding informed consent for low-risk pragmatic trials.

Dal-Ré R, Carcas AJ, Carné X, Wendler D.

BMC Med Res Methodol. 2017 Sep 18;17(1):145. doi: 10.1186/s12874-017-0424-3.

37.

Comparative effectiveness medicines research cannot assess efficacy.

Dal-Ré R, Carcas AJ.

J Clin Epidemiol. 2017 Dec;92:129. doi: 10.1016/j.jclinepi.2017.09.008. Epub 2017 Sep 14. No abstract available.

PMID:
28919461
38.

Who is willing to participate in low-risk pragmatic clinical trials without consent?

Dal-Ré R, Carcas AJ, Carné X.

Eur J Clin Pharmacol. 2017 Dec;73(12):1557-1563. doi: 10.1007/s00228-017-2332-1. Epub 2017 Sep 12.

39.

Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.

Gomez-Sanchez CI, Carballo JJ, Riveiro-Alvarez R, Soto-Insuga V, Rodrigo M, Mahillo-Fernandez I, Abad-Santos F, Dal-Ré R, Ayuso C.

Sci Rep. 2017 Sep 4;7(1):10391. doi: 10.1038/s41598-017-10912-y.

40.

2017, a key year on clinical trials transparency.

Dal-Ré R.

Med Clin (Barc). 2018 Jan 23;150(2):80-81. doi: 10.1016/j.medcli.2017.06.053. Epub 2017 Aug 31. English, Spanish. No abstract available.

PMID:
28864090
41.

Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.

Dal-Ré R.

J Eval Clin Pract. 2018 Feb;24(1):258-261. doi: 10.1111/jep.12796. Epub 2017 Jul 7.

PMID:
28685913
42.

Are article's social media mentions associated to citation counts? An analysis in highly influential medical journals.

Dal-Ré R, Mahillo-Fernández I.

Rev Clin Esp. 2018 Jan - Feb;218(1):40-42. doi: 10.1016/j.rce.2017.04.003. Epub 2017 May 29. English, Spanish. No abstract available.

PMID:
28571841
43.

Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain.

Dal-Ré R, Carcas AJ, Carné X, Wendler D.

Br J Clin Pharmacol. 2017 Sep;83(9):1921-1931. doi: 10.1111/bcp.13305. Epub 2017 Jun 11.

44.

Do opinion articles attract more social attention than original research, relative to their citation counts?

Dal-Ré R, Mahillo-Fernández I, Thelwall M.

Eur J Intern Med. 2017 Jul;42:e27-e30. doi: 10.1016/j.ejim.2017.03.016. Epub 2017 Mar 25. No abstract available.

PMID:
28351657
45.

Why prudence is needed when interpreting articles reporting clinical trial results in mental health.

Dal-Ré R, Bobes J, Cuijpers P.

Trials. 2017 Mar 28;18(1):143. doi: 10.1186/s13063-017-1899-2.

46.

Outcome reporting bias in clinical trials: why monitoring matters.

Ioannidis JP, Caplan AL, Dal-Ré R.

BMJ. 2017 Feb 14;356:j408. doi: 10.1136/bmj.j408. No abstract available.

PMID:
28196819
47.

Clinical trials transparency and access to anonymized individual participant data.

Dal-Ré R.

Rev Psiquiatr Salud Ment. 2017 Jan - Mar;10(1):1-3. doi: 10.1016/j.rpsm.2016.11.001. Epub 2016 Dec 13. English, Spanish. No abstract available.

PMID:
27986414
48.

The International Committee of Medical Journal Editors trial data sharing requirement and participants' consent.

Dal-Ré R.

Eur J Clin Invest. 2016 Dec;46(12):971-975. doi: 10.1111/eci.12694. Epub 2016 Nov 17.

PMID:
27782296
49.

Is the French clinical trials regulation discriminatory?

Dal-Ré R, Wendler D.

Eur J Intern Med. 2016 Oct;34:e35-e36. doi: 10.1016/j.ejim.2016.07.019. Epub 2016 Aug 9. No abstract available.

PMID:
27519816
50.

Prevention of selective outcome reporting: let us start from the beginning.

Dal-Ré R, Marušić A.

Eur J Clin Pharmacol. 2016 Oct;72(10):1283-1288. doi: 10.1007/s00228-016-2112-3. Epub 2016 Aug 2. Review.

PMID:
27484242

Supplemental Content

Loading ...
Support Center